ArticleDiscover oncology2026
Efficacy and safety of Osimertinib and other third-generation EGFR TKIs in advanced NSCLC: a systematic review and meta-analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the clinical efficacy, safety, and prognostic impact of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), particularly osimertinib, in patients with advanced non-small cell lung cancer (NSCLC).
methodA comprehensive search of international and Chinese databases was conducted from inception to April 2025 to identify randomized controlled trials (RCTs) assessing osimertinib in advanced NSCLC. Data extraction and quality assessment were performed independently by two reviewers using the Cochrane Handbook (version 5.3). Meta-analysis was conducted using RevMan 5.4.
resultNine RCTs involving 1,880 patients were included. Osimertinib significantly improved objective response rate (ORR) [OR = 2.99, 95% CI: 1.87–4.77] and disease control rate (DCR) [OR = 2.80, 95% CI: 1.38–5.67] compared to control therapies. The incidence of grade ≥ 3 adverse events was significantly lower in the osimertinib group [OR = 0.26, 95% CI: 0.14–0.47]. Osimertinib increased the risk of dermatologic events such as paronychia and rash but decreased gastrointestinal symptoms including nausea and vomiting.
conclusionOsimertinib is an effective and generally well-tolerated treatment option for patients with advanced NSCLC. While efficacy and safety are favorable, further research is needed to assess long-term outcomes and monitor serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.